

Genitourinary Cancer Rapid Fire Program **2023**

Contents

Welcome	1	- Ellen O'Connor	14
Agenda	2	- Gowri Shivasabesan	14
- Friday 24th November	2	- Gwen Pinches	15
- Saturday 25th November	3	- Haakan Jakobsson	15
Co-convenors	5	- Jacob Ingvar	16
- Andrishia Inderjeeth	5	- Jennifer Lim	16
- Ciara Conduit	5	- Jiasian Teh	17
Mentors	6	- Joanna Chan	17
- Ian Davis	6	- Jonathon Vundum	18
- Anna Kuchel	6	- Jordan Santucci	18
- Haryana Dhillon	6	- Katherine Ong	19
- Dickon Hayne	7	- Kelvin Yu	19
- Andrew Weickhardt	7	- Kieran Sandhu	20
- Chris Oldmeadow	7	- Kristyn Langworthy	20
- Carole Harris	8	- Kylie Lopes Floro	21
- Shankar Siva	8	- Leeatt Green	21
Special Guest	8	- Martin Hong	22
- Fiona Maclean	8	- Matthew Chau	22
Participants	9	- Milan Gunawardene	23
- Ajay Raghunath	9	- Minh-Son To	23
- Alice Thomson	9	- Mohammed Al-Zubaidi	24
- Amy Davies	10	- Muhammad Fairuz Shah Abd Karim ..	24
- Andrea Knox	10	- Nadia Hitchen	25
- Andrew Fantoni	11	- Ngie Chang Law	25
- Andrew Jensen	11	- Nicole Pringle	26
- Ashley Lee	12	- Niranjan Sathianathen	26
- Benjamin Watson	12	- Nur Adila Mokhtar	27
- Colin Williams	13	- Rhiannon Mellor	27
- Diane Lim	13	- Rosemary David	28
- Ek Leone Oh	14	- Sarah Childs	28
		- Shanuka Samaranyake	29
		- Sidney Levy	29
		- Stephanie Wakeling	30
		- Teesha Downton	30
		- Thomas Neerhut	31
		- Udit Nindra	31
		- William Harris	32
		- Zane Yang	32
		Sponsors	33

2023 ANZUP Genitourinary Cancer Rapid Fire Program

Welcome

Welcome to the 2023 ANZUP Genitourinary Cancer Rapid Fire Program.

This unique program aims to deliver a truly interactive, expert-guided understanding of the evolution of the current management of genitourinary cancers by systematically reviewing evidence gained through the performance of clinical trials. Modern day therapy has been formed by pivotal trials which have led to an understanding of how and why diagnosis and treatment pathways have developed and changed.

After significant pre-work, knowledge will be shared through peer presentations and commentary from leading GU cancer experts from Urology, Medical Oncology, Radiation Oncology and Biostatistics. The program will address bladder, kidney and testicular cancers, placed in the context of clinical care of patients, covering multimodality assessment and management of early, locally advanced and metastatic disease as well as supportive care.

Throughout the program, skills in summarising and presenting trials, understanding different types of trials, the conclusions and statistics used, the use of shared cloud resources (the Google Drive will remain a longstanding tool for you to access into the future), and the interaction with peers and experts, should make for a very rewarding experience. This program is unique to other structured courses and is not only educationally effective but also very enjoyable, with strongly positive feedback provided from previous iterations.

In 2023, we are excited to welcome attendees from the Asia Pacific region beyond Australia and New Zealand. We hope this is the first of many ANZUP events with more diverse representation from the APAC region.

We are extremely grateful to our mentors for their significant input. They will challenge you throughout the program to use all of your acquired knowledge. Thanks also to Margaret McJannett, Alice Clarke, Nicole Tankard and the wider ANZUP team for their support and administration in preparation of this year's GU Rapid Fire Program 2023.

Finally, we would like to acknowledge and thank our wonderful sponsors: Astellas, AstraZeneca, BMS, Merck and MSD for supporting this year's GU Cancer Rapid Fire Program. Without their support we would be unable to bring this exceptional learning opportunity to our future researchers.

It is our hope this course will not only help you become evidence-based practitioners but also encourage your enthusiasm for clinical trials and future involvement in ANZUP.

Andrisha Inderjeeth and Ciara Conduit
Genitourinary Cancer Rapid Fire Program Co-Convenors



Time	Friday 24 November	Presenter
1200-1250	Registration and Lunch	
1250-1300	Introduction	Andrisha Inderjeeth and Ciara Conduit
1300-1310	A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.	Joanna Chan
1310-1320	An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.	Jordan Santucci
1320-1330	Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.	Mohammed Al-Zubaidi
1330-1340	Gemcitabine versus bacille Calmette Guérin after initial bacille Calmette Guérin failure in non muscle invasive bladder cancer.	Kylie Lopes Floro
1340-1350	Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.	Matthew Chau
1350-1400	Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer.	Rosemary David
1400-1410	Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.	Amy Davies
1410-1420	Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.	Teesha Downton
1420-1430	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.	Milan Gunwardene
1430-1440	Pfister C, Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.	Andrew Fantoni
1440-1450	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.	Leeatt Green
1450-1500	Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.	Sarah Childs
1500-1530	Afternoon Tea Break	
1530-1540	Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).	William Harris
1540-1550	Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.	Nadia Hitchen
1550-1600	Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.	Martin Hong
1600-1610	Pembrolizumab as second-line therapy for advanced urothelial carcinoma.	Jacob Ingvar
1610-1620	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Cancer.	Andrew Jensen
1620-1630	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.	Haakan Jakobsson

Time	Friday 24 November <i>continued</i>	Presenter
1630-1640	Erdafitinib in locally advanced or metastatic urothelial carcinoma.	Andrea Knox
1640-1650	EV in previously treated advanced urothelial cancer.	Ek Leone Oh
1650-1700	A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09.	Ngie Chang Law
1710-1735	BLADDER CANCER CASE DISCUSSION Dickon Hayne, Shankar Siva, Andrew Weickhardt, and Haryana Dhillon	
1735-1755	RCC CASE DISCUSSION Shankar Siva, Carole Harris, and Ian Davis	
1900 onwards	DINNER at Abacus, South Yarra	

Time	Saturday 25 November	Presenter
0700-0755	BREAKFAST at the Brasserie	
0800-0810	INTRODUCTION TO ANZUP	Ian Davis
0810-0820	Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.	Muhammed Fairuz Shah
0820-0832	Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. <i>AND</i> ; A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.	Muhammed Fairuz Shah
0832-0842	Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.	Nur Adila Mokhtar
0842-0854	Adjuvant nivolumab plus ipilimumab versus placebo for localised RCC after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. <i>AND</i> ; Adjuvant pembrolizumab after nephrectomy in RCC.	Kristyn Langworthy
0854-0904	5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)	Ashley Lee
0904-0916	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.	Diane Lim
0916-0926	Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma.	Thomas Neerhut
0926-0936	Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.	Sidney Levy
0936-0946	Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial.	Jennifer Lim
0946-0956	Nivolumab versus everolimus in advanced renal-cell carcinoma.	Rhiannon Mellor
0956-1006	Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.	Ek Leone Oh
1006-1016	Lenvatinib plus pembrolizumab versus sunitinib as 1L treatment of patients with advanced RCC (CLEAR): extended follow-up from the phase 3, randomised, open-level study.	Ellen O'Connor
1016-1026	Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.	Udit Nindra
1030-1100	Morning Tea	
1100-1130	NON-CLEAR CELL RENAL CELL CANCER - HISTOLOGICAL CLASSIFICATION BY THE EXPERT	Fiona Maclean

Time	Saturday 25 November <i>continued</i>	Presenter
1130-1140	A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.	Nicole Pringle
1140-1150	Pembrolizumab plus lenvatinib as 1L therapy for advanced nccRCC (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.	Gwen Pinches
1150-1200	Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort.	Niranjan Sathianthen
1200-1210	Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.	Shanuka Samaranyake
1210-1220	Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.	Katherine Ong
1220-1230	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).	Ajay Raghunath
1230-1242	Predicting Outcomes in Men with Metastatic Nonseminomatous Germ Cell Tumours (NSGCT): Results from the IGCCCG Update Consortium. <i>AND</i> ; Survival and New Prognosticators in Metastatic Seminoma: Results from the IGC-CCG-Update Consortium.	Gowri Shivasabesan
1242-1252	Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.	Jiasian Teh
1252-1302	Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses.	Colin Williams
1302-1400	Lunch	
1400-1410	TESTES CASE DISCUSSION	Anna Kuchel, Dickon Hayne, Haryana Dhillon and Chris Oldmeadow
1410-1420	2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.	Zane Yang
1420-1430	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumours on Surveillance.	Minh-Son To
1430-1440	Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma with Limited Retroperitoneal Lymphadenopathy.	Alice Thomson
1440-1450	Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.	Kieran Sandhu
1450-1500	International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.	Jonathon Vundum
1500-1510	Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.	Stephanie Wakeling
1510-1520	TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.	Benjamin Watson
1520-1530	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 expression across the germ cell malignancy spectrum.	Kelvin Yu
1550-1610	Closing Remarks and Afternoon Tea	
		Ciara Conduit and Andrisha Inderjeeth

Co-Convenors

Andrisha
Inderjeeth



Position/Institution: Medical Oncologist at Sir Charles Gairdner Hospital and Fiona Stanley Hospital, Perth Western Australia. Clinical Research Fellow at ANZUP and the Walter and Eliza Hall Institute of Medical Research

Dr Andrisha Inderjeeth is an early career medical oncologist and the clinical research fellow at both ANZUP and the Walter and Eliza Hall Institute of Medical Research. Andrisha trained in Western Australia before completing a clinical and research fellowship in genitourinary cancers and melanoma at the Peter MacCallum Cancer Centre in Melbourne. After working as a consultant medical oncologist at The Peter MacCallum Cancer, she recently relocated back to Perth and is currently working across the two tertiary Western Australian oncology hospitals. She has an interest in clinical trials including protocol design and development.

Ciara Conduit



Position/Institution: Medical Oncologist at Peter MacCallum Cancer Centre

Dr Ciara Conduit is a Medical Oncologist working within the genitourinary and melanoma services at Peter MacCallum Cancer Centre in Melbourne. She completed her physician training in both Tasmania and Victoria, including a Fellowship within the Early Drug Development Unit at Peter MacCallum Cancer Centre in 2020. Alongside her clinical role, Ciara is engaged in genitourinary research at the Walter and Eliza Hall Institute of Medical Research and previously also at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.

Ian Davis



Position/Institute: ANZUP Chair

Professor Ian Davis is chair of the ANZUP Board and of its Scientific Advisory Committee. He is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University and Eastern Health, in Melbourne, Australia. He also honorary appointments as an Affiliate Professor of Deakin University, adjunct Associate Professor of the University of Melbourne, Associate of the University of Sydney, Honorary Professorial Fellow with The George Institute, and Adjunct Professor of University of New South Wales.

Anna Kuchel



Position/Institution: Senior Research Fellow at the Survivorship Research Group, Director of the Centre for Medical Psychology and Evidence-based Decision Making, School of Psychology, University of Sydney

Dr Anna Kuchel is a medical oncologist at the Royal Brisbane and Women's Hospital where she specialises in GU and gynae cancers. Other interests include cancer of unknown primary and junior doctor support and education.

Haryana Dhillon



Position/Institute: Senior Research Fellow at the Survivorship Research Group, Director of the Centre for Medical Psychology and Evidence-based Decision Making, School of Psychology, University of Sydney

Associate Professor Haryana Dhillon (BSc MA PhD) is a Senior Research Fellow, who co-leads the Survivorship Research Group and is a Director of the Centre for Medical Psychology and Evidence-based Decision Making, School of Psychology, University of Sydney. Haryana has more than 25 years' experience in cancer clinical research across a range of investigator-initiated cancer clinical trials. Her research interests are broad encompassing cancer survivorship, health literacy, and interventions for survivorship, symptom management, and psycho-oncology. Haryana Chairs ANZUP's Quality of Life and Supportive Care Subcommittee. Haryana is passionate about rigor in research, practical solutions to tricky problems, and doing what she can to help humans make it to the 22nd century.

Dickon Hayne



Position/Institute: Urologic Surgeon at the University of Western Australia

Professor Dickon Hayne is a urologic surgeon who leads urological research and education in urology, at the University of Western Australia. He is Head of Urology for the South Metropolitan Health Service in WA. Dickon Chairs the Bladder Urothelial and Penile (BUP) Cancer Sub-committee of ANZUP, is a SAC member, leads the BCG+MM, ZipUp and SUBDUE trials and is widely engaged in ANZUP's other subcommittees, trials and activities. His major clinical and research interests are urological cancer, in particular bladder cancer.

Andrew Weickhardt



Position/Institute: Medical Oncologist at the Olivia Newton-John Cancer and Wellness Centre in Melbourne

Associate Professor Andrew Weickhardt is a medical oncologist at the Olivia Newton-John Cancer and Wellness Centre in Melbourne. He has an interest in using immunotherapy and personalised treatments for patients with genitourinary cancer. He is actively involved in translational research investigating biomarkers of response and resistance to these treatments, and is involved in several phase 1 trials of new drugs in development, including the ANZUP trial PCR-MIB using pembrolizumab with radiation in early bladder cancer.

Chris Oldmeadow



Position/Institute: Associate Director of Data Sciences at HMRI

Associate Professor Chris Oldmeadow, as the Associate Director of Data Sciences at HMRI, spearheads a multidisciplinary team of biostatisticians, bioinformaticians, and health informaticians. They are bound by their common mission to empower clinicians and researchers in leveraging data for the enhancement of healthcare and patient outcomes.

As a pivotal member of the leadership team at HMRI, Chris has been instrumental in crafting and executing the institute's strategic vision. His approach is characterized by leading cross-functional teams and nurturing a culture that thrives on excellence and innovation.

Carole Harris



Position/Institute: Staff specialist at St George Public Hospital and Sutherland Hospital, VMO at StGeorge Private Hospital, clinical academic at the University of New South Wales

Dr Carole Harris is medical oncologist with a special interest in genitourinary cancers and breast cancer. She graduated from medicine from the University of Sydney with honours in 2002 and received her fellowship in Medical Oncology from the Royal Australian College of Physicians in 2009. She went on to complete a Masters of Medicine by Research at UNSW. Dr Harris is a staff specialist at St George Public Hospital and Sutherland Hospital and a VMO at St George Private Hospital and a clinical academic at the University of New South Wales.

Shankar Siva



Position/Institution: Radiation Oncologist at Peter MacCallum Cancer Centre

Professor Shankar Siva leads the stereotactic body radiotherapy (SABR) service at the Peter MacCallum Cancer Centre. He leads 5 international multicentre trials through the TransTasmanRadiation Oncology Group (TROG) with a focus in SABR. He has over 250 publications, with his current research focused on high-tech radiotherapy delivery, in the context of immunotherapy combinations, oligometastatic disease, kidney cancer and prostate cancer.

Special Guest

Fiona Maclean



Position/Institution: Douglass Hanly Moir Pathology

Clinical Associate Professor Fiona Maclean graduated from the University of Sydney with First Class Honours. She initially worked as a resident medical officer at the Concord Repatriation General Hospital, where she was awarded Intern of the Year. Assoc. Prof. Maclean holds the position of Clinical Associate Professor in the Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University. She has authored two chapters in the current edition of Sternberg's Diagnostic Surgical Pathology, and one chapter in the current edition of Histology for Pathologists, both of which are premier textbooks in the fields of pathology and histology. She is passionate about teaching pathology and enjoys presenting lectures to people from all walks of life. She is President of the Australasian Division of the International Academy of Pathology (IAP). Assoc. Prof. Maclean has special interests in urogenital and musculoskeletal pathology in particular.

Participants

Ajay Raghunath



Discipline: Oncology Registrar
Hospital/Institute: Austin Health
Years of training: 3
Years of practice: 0

Bio: I'm a final year oncology trainee and will be completing a fellowship in genitourinary cancers at Austin Health in 2024. Prior to this I completed my oncology training at Box Hill, Cabrini and Warnambool. I'm looking forward to further opportunities to develop my tumour stream knowledge during my upcoming fellowship and hope to subspecialise in genitourinary malignancies longer term.

Three key learning objectives:

1. Develop knowledge around neo/adjuvant treatment in bladder cancer.
2. Develop knowledge around treatment of relapsed germ cell tumours.
3. Meet and network with multidisciplinary colleagues involved in GU malignancy.

Alice Thomson



Discipline: Urology
Hospital/Institute: Peter MacCallum Cancer Centre
Years of training: 3
Years of practice: 6

Bio: Alice is an unaccredited urology registrar at Peter MacCallum Cancer Centre.

Three key learning objectives:

1. Understanding non-surgical management of urological oncology.
2. Local management of bladder cancer.
3. Generate a greater understanding of multidisciplinary care from med onc and rad onc point of view.

Amy Davies



Discipline: Medical Oncology
Hospital/Institute: Monash Health
Years of training: 3
Years of practice: 0

Bio: Dr Amy Davies is a final year medical oncology advanced trainee. Amy obtained her medical degree at University of Notre Dame (Fremantle) and internship at Fiona Stanley Hospital (Perth). She completed Basic Physician Training at Monash Health and was subsequently granted a position on the Victorian Medical Oncology Training Program. Her first year of advanced training was split between Latrobe Regional Hospital and Alfred Health. Amy also holds Bachelor of Clinical Sciences (SCU), Masters of Public Health (USyd) and Masters of Medicine (USyd). She has published several peer-reviewed papers, presented research at national conferences and has contributed three treatment protocols to the leading Australian oncology website eviQ.

Three key learning objectives:

1. Better understand the staging and management of testicular cancer.
2. Develop a roadmap to 1L ccRCC management and what to do with nccRCC.
3. Better understanding of ICI in urothelial cancer.

Andrea Knox



Discipline: Medical Oncology
Hospital/Institute: Alfred Health
Years of training: N/A
Years of practice: 1

Bio: Andrea is a medical oncologist working in a clinical trials fellow role at The Alfred. She has worked at the Peter MacCallum Cancer Centre, and Barwon Health, and trained in Victoria and New South Wales.

Three key learning objectives:

1. Improve my confidence with less common GU cancer management: early bladder cancer, testicular germ cell tumours.
2. Engage with mentors and experts in GU cancer management, and interested colleagues.
3. Improve my ability to critically appraise and apply literature to my everyday practice.

Andrew Fantoni



Discipline: Medical Oncology

Hospital/Institute: Fiona Stanley Hospital

Years of training: 3


Years of practice: 7

Bio: Dr Andrew Fantoni is a Medical Oncology Advanced Trainee working at Fiona Stanley Hospital in Perth, Western Australia. He was awarded a WA Cancer and Palliative Care Network Fellowship in 2023 to conduct research in the epidemiological factors and treatment outcomes of Aboriginal and rural populations with lung cancer. He also undertakes a monthly regional Oncology clinic in Esperance, 10 hours from Perth. He has a passion to improve regional and remote cancer outcomes.

Three key learning objectives:

1. Expand knowledge of testicular trials.
2. Expand knowledge of bladder trials.
3. Expand knowledge of RCC trials.

Andrew Jensen



Discipline: Medical Oncology

Hospital/Institute: Western Cancer Centre Dubbo

Years of training: N/A

Years of practice: 1

Bio: Dr Andrew Jensen is a medical oncologist at the Western Cancer Centre Dubbo.

Three key learning objectives:

1. Increase familiarity with management of recurrent non muscle invasive bladder cancer.
2. Improve understanding of management options for recurrent testicular germ cell tumours.
3. Improve understanding of TKI sequencing in advanced renal cell carcinoma.

Ashley Lee



Discipline: Urology

Hospital/Institute: Fiona Stanley Hospital

Years of training: 4

Years of practice: 1

Bio: Ashley Lee is a urology service registrar at Fiona Stanley Hospital with aspirations to apply for urology training in the coming years. Commencing 2024 she will fulfil the role of the research registrar. She has interest in the environmental footprint of urological practices and creating solutions specific to the practice. In the future she hopes to be involved in more projects which will enhance the safety and service delivery to urology patients in the context of sound environmental principles. Ashley has a passion for sharing ideas and collaborating with others to instigate change in practice to create a more environmentally sustainable healthcare system.

Three key learning objectives:

1. Become familiarised with the most up to date results of clinical trials of GU cancers.
2. Develop skills in working in multi disciplinary teams.
3. Collaborate on the creation of evidence based treatment protocols based on the newest research.

Benjamin Watson



Discipline: Medical Oncology

Hospital/Institute: Toowoomba Hospital

Years of training: 3

Years of practice: 1

Bio: I am a Physician in Medical Oncology and General Medicine at Toowoomba Hospital, Queensland. After originally training in Melbourne, I moved to the Northern Territory to complete General Medicine training and have since completed Medical Oncology training in Queensland. This is my first year as an Oncologist, my practice is in the public hospital with a broad range of cancer streams. I would consider myself a general oncologist in a rural setting. I would like to provide good standard of care to patients in a rural setting, hence my enrolment in this program.

Three key learning objectives:

1. Understand the evolution of prostate cancer management.
2. Know the role of lutetium and when to refer.
3. Determine correct sequencing for bladder cancer.

Colin Williams



Discipline: Medical Oncology

Hospital/Institute: PMCC

Years of training: 3

Years of practice: 7

Bio: A third year medical oncology Advanced Trainee at Peter MacCallum Cancer Centre and President of the Victorian Medical Oncology Training Program with a particular interest in genitourinary cancers.

Three key learning objectives:

1. Seeking clarity in ever changing prostate cancer space.
2. Explore new therapies in bladder cancer and sequence of therapies.
3. Understand management of relapsed disease in testicular cancer.

Diane Lim



Discipline: Radiation Oncology

Hospital/Institute: Bendigo Radiotherapy Centre, Peter MacCallum Cancer Centre

Years of training: 1

Years of practice: 2

Bio: A Radiation Oncology registrar based in Bendigo with a passion for teaching and research. She loves being a part of a team of healthcare professionals that help to expand radiotherapy services outside of metropolitan cities – striving for equitable access for all.

Three key learning objectives:

1. Learn when there's still a role for local control in the case metastatic RCC and how much that benefit can be better quantified.
2. Learn what systemic options patients have with metastatic germ cell tumours and how those treatment options affect the side effect profile experienced with palliative radiotherapy.
3. Better appreciate the evidence behind the various treatment management options of muscle invasive bladder tumours and how further genetic profiling of these tumours can alter treatment preferences.

Ek Leone Oh



Discipline: Medical Oncology
Hospital/Institute: Fiona Stanley Hospital
Years of training: 2
Years of practice: 8

Bio: Leone is a second-year medical oncology trainee based at Fiona Staley Hospital in Western Australia.

Three key learning objectives:

1. Management GU cancers.
2. Interpretation of trials.
3. Mentorship.

Ellen O'Connor



Discipline: Urology
Hospital/Institute: Bendigo Health
Years of training: 8
Years of practice: N/A

Bio: Ellen is a third-year urology trainee currently placed in Bendigo. She has undertaken her prior training years at Western and Barwon Health. Ellen is the current trainee representative for the USANZ Board of Urology.

Three key learning objectives:

1. Overview of landmark trials.
2. Multidisciplinary discussions.
3. Education for upcoming fellowship examination.

Gowri Shivasabesan



Discipline: Medical Oncology
Hospital/Institute: Campbelltown Hospital
Years of training: 1
Years of practice: 1

Bio: I am a first year medical oncology advanced trainee currently working at Campbelltown Hospital, as part of the South West Sydney/St Vincent's Network. My interests are in improving patient-centred outcomes and quality improvement, as well as trainee wellbeing.

Three key learning objectives:

1. Consolidate understanding of investigating and managing GU malignancies.
2. Learn about emerging research and treatment.
3. Meet colleagues interested in GU cancers in order to build networks for future collaborations.

Gwen Pinches



Discipline: Medical Oncology
Hospital/Institute: Dunedin Hospital, NZ
Years of training: FRACP complete
Years of practice: 1.5


Bio: I am a consultant medical oncologist in beautiful Dunedin, New Zealand, specialising in GU and GI cancers. I practice in public only at present, and have been a consultant for 18 months. I have a particular interest in making the most of a very limited number of available drugs! But I remain ever hopeful that we in NZ will join the first world one day and hence I want to be ready.

I completed my basic and advanced training in Dunedin and Wellington. I'm an adopted Kiwi now having moved from the UK in 2015. Prior to that was undergraduate natural sciences, medical school, and 4 years of NHS graft. I love cancer nerding, but what I love even more is getting outside and active in green spaces. Come talk to me about Dunedin!

Three key learning objectives:

1. Cementing of data behind GU practice.
2. Greater familiarity with treatments not available in NZ GU oncology (e.g. immunotherapy).
3. Opportunity to meet with experts in the field, hear about cases, make contacts for networking.

Haakan Jakobsson



Discipline: Medical Oncology
Hospital/Institute: The Alfred
Years of training: 4 years Medical Oncology (including fellowship)
Years of practice: 0 as Medical Oncologist

Bio: Haakan is a medical oncology fellow in early phase clinical trials at the Alfred Hospital Melbourne, He did his training in Queensland across a broad range of hospitals including in regional areas. Haakan has an interest in genitourinary cancers, melanoma, lung cancer, and precision oncology. When he isn't working, he likes exploring the great outdoors.

Three key learning objectives:

1. Understanding of new developments in GU oncology.
2. Understanding of the role of the multidisciplinary team and role of other specialties in treatment of GU malignancies.
3. Comprehensive understanding of current best practice in GU oncology.

Jacob Ingvar




Discipline: Urology
Hospital/Institute: Peter Mac
Years of training: N/A
Years of practice: 6

Bio: I became a Fellow European Board of Urology (FEBU) in 2017 and have been working as a specialist at the Urology Department at Skåne University Hospital in Sweden. Since February 2023 I have been doing a 12-month Fellowship at Peter Mac in Melbourne. As part of my PhD, at the Department of Translational Medicine at Lund University, I perform studies on the use of PSMA PET/CT for prostate cancer staging.

Three key learning objectives:

1. Latest testicular cancer.
2. Latest bladder cancer.
3. Latest kidney cancer.

Jennifer Lim



Discipline: Medical Oncology
Hospital/Institute: St George Hospital, Sydney
Years of training: 3
Years of practice: 3

Bio: Jennifer Lim is a staff specialist medical oncologist at St George Hospital in Sydney focusing on neuroendocrine tumours, head and neck tumours and more recently GU cancer. She trained at the Chris O'Brien Lifehouse and Concord Hospital before a clinical fellowship year at the Kinghorn Cancer Centre. Jennifer is currently undertaking her PhD in translational science exploring single-cell sequencing of peripheral immune cells and predictive biomarkers at the Garvan Institute of Medical Research. She enjoys spending the rest of her (limited) time with her young family and Labrador and experimenting with Thermomix recipes.

Three key learning objectives:

1. Improve knowledge in prostate cancer.
2. Improve knowledge and confidence in bladder cancer.
3. Network with GU oncology staff - I am new to the discipline!

Jiasian Teh



Discipline: Urology
Hospital/Institute: Eastern Health
Years of training: 2
Years of practice: 9

Bio: Jiasian is a urology trainee who has recently completed a PhD in penile cancer at Peter MacCallum Cancer Centre.

Three key learning objectives:

1. Further understanding of management and evidence in GU cancer.
2. Appreciation of literature supporting management of GU cancer.
3. Understanding of landmark trials.

Joanna Chan



Discipline: Oncology
Hospital/Institute: Peter Mac
Years of training: 4
Years of practice: 0

Bio: Dr Joanna Chan is a Medical Oncology Fellow at the Peter MacCallum Cancer Centre specialising in melanoma and genitourinary cancers. She obtained her medical degree from Deakin University (VIC) and completed Basic Physician Training at Eastern Health and specialty training in Medical Oncology via Eastern Health, St Vincent's Hospital and the Peter Mac in Melbourne. Prior to medicine, Joanna previously completed a Bachelor of Biomed Sci (Hons) and a PhD in Biochemistry and Molecular Biology via Monash University/Peter Mac examining the role of AKT pathway in cancer.

Three key learning objectives:

1. Gain confidence in managing non-prostate GU malignancies.
2. Refine presentation skills.
3. Networking with people with GU interests.

Jonathon Vundum



Discipline: Medical Oncology
Hospital/Institute: Coffs Harbour Health Campus
Years of training: 1 (1st year AT)
Years of practice: 8

Bio: Currently a first-year medical oncology advanced trainee in Coffs Harbour and will be doing my second year in Newcastle, NSW. I am from Birmingham, UK, studied in Edinburgh and moved to Australia for a better life after my PGY2 year. I have since married an Australian nurse and we have an 18-month-old boy. I enjoy cycling, trying to surf and play 6-a-side soccer each week.

Three key learning objectives:

1. Improve knowledge on GU cancers (currently an area where my knowledge is weaker).
2. Improve my ability in analysing oncological papers and presenting to small groups.
3. Networking with other trainees or junior consultants in this field.

Jordan Santucci



Discipline: Surgery
Hospital/Institute: Royal Melbourne Hospital
Years of training: 3 post graduate practice + 4 years medical school
Years of practice: 3 years (internship, two years as resident)

Bio: Jordan is an unaccredited surgical registrar at Royal Melbourne Hospital currently undertaking research in Urology at the Peter MacCallum Cancer Centre with the Genitourinary Oncology unit.

Three key learning objectives:

1. Work-up and management of renal cell carcinoma.
2. Work-up and management of urothelial cancers.
3. Evidence-base behind neoadjuvant and adjuvant treatments for urothelial cancers.

Katherine Ong



Discipline: Urology

Hospital/Institute: Fiona Stanley Hospital

Years of training: Unaccredited Registrar - 4th Year of Reg Service

Years of practice: PGY7 (as of 2023)

Bio: Dr Katherine Ong is a Urology Registrar and the current Urology Research Registrar at Fiona Stanley Hospital in Perth, Western Australia. She has a keen interest in urothelial and renal cancers, and is working on several research projects, including the use PSMA PET-CT in renal cell carcinoma and the SUBDUE-1 trial evaluating the safety of sub-urothelial injection of durvalumab in patients with bladder cancer.

Three key learning objectives:

1. Consolidate knowledge about trials in metastatic prostate cancer.
2. Delve into the role of different staging modalities - particular interest in RCC.
3. Learn about adjuvant trials for advanced RCC.

Kelvin Yu



Discipline: Radiation Oncology

Hospital/Institute: Peter MacCallum Cancer Centre

Years of training: 5

Years of practice: 1

Bio: Dr Kelvin Ken Yu is a GU/Sarcoma Radiation Oncology Fellow at Peter MacCallum Cancer Centre. He is a graduate of the University of Santo Tomas Faculty of Medicine and Surgery in Manila, Philippines and has completed his residency training in Radiation Oncology at Benavides Cancer Institute, University of Santo Tomas Hospital, Philippines.

Three key learning objectives:

1. Become updated with the most recent evidence based treatment recommendations.
2. Become familiar with ongoing and upcoming clinical trials for GU malignancies.
3. Further understanding of landmark clinical trials in the management of GU cancers.

Kieran Sandhu



Discipline: Urology

Hospital/Institute: Royal Melbourne Hospital

Years of training: 2

Years of practice: 2

Bio: My name's Kieran and I'm a resident with a keen interest in Urology. I am interested in all facets of urological oncology and improving the transition between bench to bedside. Outside of medicine I love all things endurance sports!

Three key learning objectives:

1. Cultivating skills to have multi-disciplinary discussions for GU cancer management and understanding how to extrapolate results of the latest research and applying this to patient care.
2. Solidifying my understanding of current key trials in the management of GU Cancer so that I am able to explain to my patients outcomes of landmark trials in simple, non-technical language.
3. Developing my understanding of the utility of surgical vs medical vs radiation management in key GU cancers and being able to discuss these options with patients and my colleagues to deliver the best possible, patient-centred outcomes.

Kristyn Langworthy



Discipline: Medical oncology

Hospital/Institute: FSH

Years of training: 1

Years of practice: 1

Bio: 1st year advanced trainee at Fiona Stanley Hospital in Western Australia. Also training in palliative care and general medicine. Interest in research and currently in enrolled in a Masters of Research through the University of Western Australia.

Three key learning objectives:

1. Evidence based approach to first line treatment for common GU cancers.
2. Evidence based approach to surveillance.
3. New treatments for GU cancer treatment.

Kylie Lopes Floro



Discipline: Radiation Oncology

Hospital/Institute: Princess Alexandra Hospital - Raymond Terrace

Years of training: 6

Years of practice: 9

Bio: Kylie Lopes Floro is a senior radiation oncology trainee at Princess Alexandra Hospital (Raymond Terrace Campus). Whilst undergoing training she has applied for and obtained grants to research the effect of radiation and cigarette smoke on head and neck cancer cells and the potential to generate cancer stem cells. She identified that the two can result in the cells undergoing the process of epithelial mesenchymal transition; in effect displaying a more aggressive phenotype before clonogen death occurs. In addition to this, she has performed next generation sequencing to identify the underlying molecular process.

Prior to medicine she undertook a Science degree at Sydney University majoring in molecular biology and genetics. This was followed by a PhD and post-doctoral fellowship in embryology and developmental genetics at the Victor Chang Cardiac Research Institute and the University of New South Wales.

Three key learning objectives:

1. Increased knowledge of RCC, muscle invasive bladder cancers and germ cell tumours - from a general management perspective but also specifically with a radiation oncology perspective.
2. Increased knowledge of publications driving management.
3. Increasing my knowledge of current research / trials investigating management of these cancers.

Leeatt Green



Discipline: Oncology

Hospital/Institute: Eastern health

Years of training: 2

Years of practice: 6

Bio: My name is Leeatt, I am a second year oncology AT from Melbourne. When I'm not at work, I spend time with my husband and 2 gorgeous girls who are 3 and 1 years old. I love a good hamburger and have tried over 86 different hamburger stores in search of the perfect one!

Three key learning objectives:

1. Understand 1st 2nd line SOC for GU cancer.
2. Improved interpretation of clinical trials and application of these to clinical practice including limitations of various studies.
3. Liaise with consultants in the GU area and opportunities for research.

Martin Hong



Discipline: Medical Oncology
Hospital/Institute: Liverpool Hospital
Years of training: 5
Years of practice: 10

Bio: Dr Martin Hong is a Clinical Trials Fellow working at Liverpool Hospital in Sydney with a focus on early phase trials. Martin has recently received his fellowship in Medical Oncology from the Royal Australasian College of Physicians and has tumour stream interests in genitourinary and lung cancers.

Three key learning objectives:

1. Learn the latest treatments in prostate cancer.
2. Refresh knowledge in management of bladder cancer.
3. Better understand the patient impact of GU treatments.

Matthew Chau



Discipline: Urology
Hospital/Institute: Sir Charles Gairdner Hospital, Perth, WA
Years of training: Starting SET training next year
Years of practice: 2.5 years unaccredited urology

Bio: I am currently a urology unaccredited registrar working in Sir Charles Gairdner Hospital, Perth.

I have a particular interest in urological oncology and the delicate surgeries involved (particularly renal malignancy). I've requested to participate in the ANZUP Rapid Fire program to better understand the role of surgery in GU cancer management and key landmark papers that has influenced the overall management.

In half of my spare time, I play basketball. The other half is spent regretting thinking I'm young with healthy joints.

Three key learning objectives:

1. Understand the multidisciplinary GU Cancer Management including the key challenges, advancements, and emerging trends in the field. I would like to gain a better appreciation for the role of all specialties involved in managing GU cancer, when to refer and what options can be provided to my patients.
2. Update myself regarding landmark Clinical Trials in GU Cancer. I want to critically analyse and learn about landmark clinical trials in GU cancer.
3. Apply Evidence-Based Practices when I am a Urology trainee next year. Understand the rationale of choosing certain treatment options for patients, rather than because of practice preferences.

Milan
Gunawardene



Discipline: Urology
Hospital/Institute: Royal Perth Hospital
Years of training: 7
Years of practice: 10

Bio: Dr. Milan Gunawardene graduated from the Faculty of Medicine, University of Ruhuna, Sri Lanka, in 2012 with a second-class upper division and distinctions in anatomy, physiology, biochemistry, microbiology, and surgery. He received his MD in surgery from the University of Colombo, Sri Lanka, in March 2021. He completed MRCS Glasgow in August 2021. He is a lecturer in surgery in the Faculty of Medicine, University of Ruhuna, Sri Lanka. Currently, he is working as a Urology Fellow at Royal Perth Hospital.

Three key learning objectives:

1. Refresh knowledge on key landmark trials.
2. Study new landmark trials.
3. Practice evidence based urology.

Minh Son-To



Discipline: Radiology
Hospital/Institute: South Australia Medical Imaging/Royal Adelaide Hospital
Years of training: 1
Years of practice: PGY6

Bio: Dr To is a Radiology Registrar at South Australia Medical Imaging (SA Health) and Early Career Clinician Scientist. He has undergraduate backgrounds in Pharmacy, and Mathematical and Computer Science. He undertook a joint MD/ PhD program in neuroscience at Flinders University and the Australian National University, graduating in 2017. He conducts his current research as an affiliate member of the Flinders University Health Data and Clinical Trials group, and is also a Visiting Research Fellow at the Australian Institute for Machine Learning (University of Adelaide).

Dr To's current research is focused on artificial intelligence (AI) methods in medical imaging, with a particular emphasis on clinical translation. He is currently building a large multimodal database of prostate cancer imaging, which he will use to develop AI systems to improve risk stratification and prognostication of men with prostate cancer.

Three key learning objectives:

1. Greater understanding of current practice in management of GU cancers.
2. Role of imaging in diagnostic evaluation, staging and follow-up of GU cancers.
3. Awareness of landmark trials in GU cancers.

Mohammed
Al-Zubaidi



Discipline: Urology

Hospital/Institute: Fiona Stanley Hospital

Years of training: Commencing first year of training next year (2024)

Years of practice: 4

Bio: I am a Urology Registrar at Fiona Stanley Hospital in Western Australia, I am going to start Urology training in WA in 2024. I completed my medical degree in Iraq and migrated to Australia for a new start. I am now a father of two. I am enjoying my life in and out of working hours.

Three key learning objectives:

1. Learn about advancements in bladder cancer treatment.
2. Learn more about the treatment options of RCC.
3. Get more knowledge on testicular tumours.

Muhammad Fairuz
Shah Abd Karim



Discipline: Urology

Hospital/Institute: University Malaya Medical Centre (UMMC)

Years of training: 2

Years of practice: 4

Bio: Muhammad Fairuz Shah Abd Karim is a Clinical Specialist in Urology and Lecturer in Universiti Teknologi MARA (UiTM) with a demonstrated history of working in the higher education industry. Skilled in Research, Teamwork, Teaching, and Leadership and have strong education professional with a Master's degree focused in General Surgery from University of Malaya in 2021. He is currently undergoing subspecialty training in Fellowship of Urology under Malaysian Board of Urology in University Malaya Medical Centre (UMMC) Kuala Lumpur, Malaysia.

Three key learning objectives:

1. Update about latest approach to treat and manage genitourinary cancer.
2. Learn from the experience and thought from the experts in the fields of genitourinary cancer.
3. Learn and get myself expose on how to conduct and perform clinical trial especially in term of GU cancers patients.

Nadia Hitchen



Discipline: Medical Oncology
Hospital/Institute: Peter MacCallum
Years of training: 3
Years of practice: N/A

Bio: Currently I am a Medical Oncology fellow at Peter MacCallum Cancer Centre (phase 1/GU), having done my previous medical oncology training in Auckland, NZ. I graduated from medical school in the UK before making the move to the southern hemisphere. I am passionate about GU oncology and continuing to be involved with trials to improve the care and outcomes for GU cancer patients.

Three key learning objectives:

1. Discussion and development of knowledge for early stage bladder cancers.
2. Management of RCC when to refer for local therapies vs surgery and how to navigate sequencing of treatment in context of recent approvals and evidence.
3. Management of advanced bladder cancer, local symptoms and chemotherapy/immunotherapy escalations and de escalation.

Ngie Chang Law



Discipline: Medical Oncology
Hospital/Institute: Fiona Stanley Hospital
Years of training: 3
Years of practice: 1

Bio: Final year medical oncology trainee based at Fiona Stanley Hospital WA with special interest in GU cancers.

Three key learning objectives:

1. Multidisciplinary management of bladder cancer, role of chemoradiotherapy in locally advanced disease.
2. Management of metastatic germ cell tumours- systemic therapy vs role of RT and surgery.
3. Sequencing of treatment for metastatic clear cell RCC.

Nicole Pringle



Discipline: Medical Oncology
Hospital/Institute: Gold Coast University Hospital
Years of training: 3rd
Years of practice: 3

Bio: I'm currently a final year trainee at the Gold Coast University Hospital. I've completed my initial two years of training in regional QLD and 12 months in Brisbane. I'm currently studying a Masters of Medicine in Clinical Epidemiology at the University of Sydney part time. My interests include GI, GU and Thoracic oncology where I've recently had two abstracts presented as posters at the World Conference Lung Cancer in Singapore. I will be starting as a clinical fellow at Gold Coast University Hospital in 2024.

Three key learning objectives:

1. Enhance my understanding of the current metastatic low volume prostate cancer management landscape.
2. Gain a better understanding of the management in metastatic bladder cancer.
3. Consolidate my knowledge in the adjuvant setting of germ cell tumours.

Niranjan Sathianathen



Discipline: Urology
Hospital/Institute: Western Health
Years of training: SET3
Years of practice: 7

Bio: Niranjan is a SET3 urology trainee at Western Health. He is undertaking a PhD on the health economics of prostate cancer diagnosis and management but has an interest in all aspects of urologic oncology.

Three key learning objectives:

1. More in-depth understanding of literature.
2. Networking with colleagues.
3. Identify knowledge gaps and evidence free spaces.

Nur Adila Mokhtar



Discipline: Clinical Oncologist

Hospital/Institute: University Malaya, Kuala Lumpur, Malaysia

Years of training: 7 years training - Specialist registrar

Years of practice: 2 years (as a consultant clinical oncologist)

Bio: Dr Nur Adila Mokhtar is a Clinical Oncologist and a Medical Lecturer at the department of Clinical Oncology, University Malaya, Kuala Lumpur, Malaysia.

She obtained her medical degree from University of Sheffield and pursued her formal medical training in the UK. She has post medical certificate including MRCP UK, FRCR Oncology London and was awarded the Certificate Completion of Training (CCT UK) by the General Medical Council, UK. She has special interest in breast, genitourinary, lung and gynaecological cancer.

Three key learning objectives:

1. To enhance knowledge and expertise in GU medicine with the aim to improve in patients' care.
2. To be able to apply evidence based in real life practice to optimise patients' care.
3. To gain fundamental knowledge on clinical trials design, process and prepare to face the challenges.

Rhiannon Mellor



Discipline: Medical Oncology

Hospital/Institute: Chris O'Brien Lifehouse

Years of training: 3 (in medical oncology)

Years of practice: 3 (in medical oncology)

Bio: I'm a Medical Oncology Fellow at Chris O'Brien Lifehouse in Sydney NSW and a PhD student at the Garvan Institute of Medical Research. I have a keen interest in genitourinary cancers. My PhD research is focused on prostate cancer, in particular the interaction between the androgen receptor and aberrant lipid metabolism in metastatic prostate cancer.

Three key learning objectives:

1. An overview of the cornerstone trials underlying our current clinical practice in genitourinary cancer care.
2. A closer look specifically at the evidence underlying practice in prostate cancer care (my current major area of practice and research).
3. Meeting others interested in or currently practicing in genitourinary oncology.

Rosemary David



Discipline: Medical Oncology

Hospital/Institute: Fiona Stanley Hospital

Years of training: 1

Years of practice: 8

Bio: I'm a first year Advanced Trainee based in Perth. I have an interest in working Regionally in the future.

Three key learning objectives:

1. Learn more about the evidence for current treatments utilised in GU cancers.
2. Hear about new developments in GU cancer that may help improve outcomes in the future.
3. Understand how GU specific oncologists make decisions surrounding treatment for patients.

Sarah Childs



Discipline: Medical Oncology

Hospital/Institute: Liverpool Hospital

Years of training: 1

Years of practice: 5

Bio: I am a first year medical oncology advanced trainee undertaking training in the Sydney South West network and I am currently based at Liverpool Hospital where I have completed all of my former medical training. I have clinical interests in breast, genitourinary and gynaecological cancers. My active research endeavour involves the assessment of prognostic scores in early phase clinical trials.

Three key learning objectives:

1. Consolidate knowledge on management of GU malignancies.
2. Develop skills on critical appraisal of research and presentation skills.
3. Network with other colleagues.

Shanuka
Samaranyake



Discipline: Radiation Oncology
Hospital/Institute: Lismore Base Hospital
Years of training: 2 (2nd year Advanced Trainee)
Years of practice: 2

Bio: My name is Shanuka Samaranyake and I am currently a second year Radiation Oncology Advanced Trainee based in NSW. My background also includes an undergraduate degree in Actuarial Studies/Finance as well as a recently completed MPH and I am eager to further develop my research interests by combining these fields by pursuing research into health economics and health equity.

From the ANZUP Rapid Fire GU Cancer Program I hope to further develop my knowledge in GU cancer management and broaden my network within the GU field to pursue research/collaborations in the future.

Three key learning objectives:

1. Understand the management techniques for different GU cancers and liaise with colleagues from other specialities.
2. Networking and discussion regarding trial setup from leaders in the field of GU cancer, to help with establishing new trials.
3. Increased understanding of upcoming trials and latest evidence for management of GU cancers.

Sidney Levy



Discipline: Radiology and Nuclear Medicine
Hospital/Institute: Peter MacCallum Cancer Centre
Years of training: 6
Years of practice: 5.5

Bio: Dr Levy is a dual qualified Radiologist and Nuclear Medicine Specialist with local and international postgraduate fellowship training in urological, head and neck and musculoskeletal PET CT and MRI. He has considerable experience as a lead radiologist and nuclear medicine specialist in genitourinary oncology multidisciplinary meetings at Peter MacCallum Cancer Centre, Cabrini Health and Monash Health. He has public appointments with Peter MacCallum Cancer Centre, the Royal Melbourne Hospital and Monash Health, and private appointments with I-MED Radiology Network and Cabrini Health in Melbourne. As a Senior Lecturer through the University of Melbourne, he maintains an active educational and research programme in genitourinary oncology. completed his PhD on the biology of lymphoedema through the Ludwig Institute of Cancer Research, Peter MacCallum Cancer Centre and University of Melbourne.

Three key learning objectives:

1. To obtain a better understanding of therapeutic options and the role of imaging in advanced bladder cancer.
2. To obtain a better understanding of therapeutic options and the role of imaging in advanced renal cell carcinoma.
3. To obtain a better understanding of therapeutic options and the role of imaging in testicular germ cell tumour.

Stephanie Wakeling




Discipline: Medical Oncology
Hospital/Institute: Peter Mac
Years of training: 2.5
Years of practice: 2.5

Bio: I'm currently a third-year oncology advanced trainee at Peter MacCallum Cancer Centre here in Melbourne. Outside of work, I spend most of my time chasing after our energetic, blueberry obsessed toddler and escaping down the coast for the weekend when possible.

Three key learning objectives:

1. Better understanding of evidence regarding treatment in bladder cancer.
2. Improve knowledge regarding management of testicular cancer.
3. Better understanding of new treatment paradigms for RCC.

Teesha Downton



Discipline: Medical Oncology
Hospital/Institute: Royal Darwin Hospital
Years of training: Completed medical oncology advanced training in 2022
Years of practice: 1st year consultant

Bio: I am a medical oncologist at Royal Darwin Hospital with particular interest in treating genitourinary, breast, gynaecological and skin cancers.

Three key learning objectives:

1. Become familiar with the history and evidence base behind current GU treatment guidelines.
2. Appreciate the evidence gaps and controversies in GU treatment.
3. Discussions about management in the Australian context e.g. less ready access compared to US to some therapies.

Thomas Neerhut



Discipline: Urology Resident
Hospital/Institute: Barwon Health
Years of training: 3
Years of practice: 3

Bio: Current urology resident at Barwon Health (Geelong). Urology registrar as of 2024 and very interested in gaining a greater awareness of contemporary evidence based medicine in genitourinary oncology.

Three key learning objectives:

1. To learn more regarding novel treatments for localised, non muscle invasive and muscle invasive bladder cancer.
2. Explore the role of molecular staging in bladder cancer and the role of biomarkers in GU cancers.
3. Discuss and familiarise myself with the latest information on supportive cares and the role of exercise therapies etc. in GU cancer survivorship.

Udit Nindra



Discipline: Medical Oncology
Hospital/Institute: Liverpool Hospital
Years of training: 3
Years of practice: 0

Bio: I am a current final year medical oncology advanced trainee at Liverpool Hospital, undertaking a clinical trials focused fellowship. In addition, I am undertaking a PhD through Western Sydney University looking into biomarkers of response in patients with metastatic prostate cancer. I have a keen interest in genitourinary cancers and am currently working with Prof. Wei Chua in this clinical space. Addition to this, I have an interest in clinical trials with specific interests in biomarkers of clinical response and resistance to treatment. I am excited to learn more about management of GU malignancies during this course.

Three key learning objectives:

1. Keen interest in GU cancer with current PhD in same topic.
2. Renal cell carcinoma update.
3. Testicular cancer update.

William Harris



Discipline: Medical Oncology

Hospital/Institute: Auckland City Hospital

Years of training: 3rd year Advanced Training Medical Oncology

Years of practice: 7th year practising as a doctor

Bio: I'm Will. I'm currently working as a Research Fellow at Auckland Clinical Trial Centre in Early phase and Thoracic oncology. I have undertaken my Medical Oncology training thus far at Auckland City Hospital. I have a keen interest in GU, GI, and Thoracic malignancies. Outside of work I enjoy distance running, reading, and trying to keep up with my toddler!

Three key learning objectives:

1. Enhance skills of clinical trial critical appraisal.
2. Improve understanding bladder cancer treatment.
3. Improve understanding of RCC treatment.

Zane Yang



Discipline: Medical Oncology

Hospital/Institute: Royal Brisbane and Women's Hospital

Years of training: 2

Years of practice: 0


Bio: Hello, my name is Zane. I'm a medical oncology 2nd year Advanced Trainee from Queensland, currently working at the Royal Brisbane and Women's Hospital. As a Queensland trainee, I have rotated through a number of different centres around Queensland including Cairns, Sunshine Coast and Gold Coast University Hospitals. I am open to most cancer streams at present however I'm favouring genitourinary and lung.

Three key learning objectives:

1. More familiarity with literature.
2. Practice tips on genitourinary cancers.
3. Networking with other medical oncologists and trainees.

Sponsors





Genitourinary Cancer Rapid Fire Program 2023